In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugs

Pharmaceutical Research

Volumn 15, Issue 8, 1998, Pages 1189-1195

  Joshi, Rajashree ^a   Arora, Vikram ^b   Desjardins, John P ^c   Robinson, Dennis ^a   Himmelstein, Kenneth J ^d   Iversen, Patrick L ^e  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Research Department   (United States)

^e Antivirals Inc   (United States)

Author keywords

In situ gel; Macromolecular drugs; Poly(ethylene glycol); Poly(methacrylic acid); Sustained delivery

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENZYME ASSAY; GEL; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED DRUG RELEASE;

ANIMALS; BASE SEQUENCE; DIURESIS; DRUG CARRIERS; INFUSIONS, PARENTERAL; MALE; OLIGONUCLEOTIDES; POLYETHYLENE GLYCOLS; POLYMETHACRYLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; SLEEP;

EID: 0031713190     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011979505697     Document Type: Article

References (23)

1. T. Tice and S. Tabibi. Parenteral Drug Delivery: Injectables. In A. Kydonieus (eds), Treatise on Controlled Drug Delivery, Marcel Dekker, Inc., 1992, pp. 314-336.
2. A. Kharenko and V. Kemenova. Controlled release from oral formulations based on interpolymeric polymethacrylic-polyethylene glycol complex. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22:232 (1995).
3. C. Bell and N. Peppas. Poly(methacrylic acid-g-ethylene glycol) hydrogels as pH responsive biomedical materials. Mat. Res. Soc. Symp. Proc. 331:199-204 (1994).
4. B. Haglund, R. Joshi, and K. Himmelstein. An in situ gelling system for part-literal delivery. J Control. Rel. 41:229-235 (1995).
5. M. Shively, B. Coonts, W. Renner, J. Southard, and A. Bennett. Physico-chemical characterization of a polymeric injectable implant delivery system. J Control. Rel. 33:237-243 (1995).
6. W. Lambert and K. Peck. Development of an in situ forming biodegradable polylactide-co-glycolide system for the controlled release of proteins. J. Control. Rel. 189-195 (1995).
7. J. Desjardins and P. Iversen. Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J. Pharmacol. Exp. Ther. 275:1608-1613 (1995).
8. K. Thummel, D. Shen, T. Podoll, K. Kunze, W. Trager, P. Hartwell, V. Raisys, C. Marsh, J. McVicar, D. Barr, J. Perkins, and R. Carithers Jr. Use of midazolam as a human cytochrome P450 3A probe. J. Pharmacol. Exp. Ther. 271:549-556 (1994).
9. P. Watkins. Non-invasive test of CYP3A enzymes. Pharmacogenetics 4:171-184 (1994).
10. J. Desjardins, B. Sproat, B. Beijer, M. Blaschke, M. Dunkel, W. Gerdes, J. Ludwig, V. Reither, T. Rupp, and P. Iversen. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J. Pharmacol. Exp. Ther. 278:1419-1427 (1996).
11. M. Franklin and R. Estabrook. On the inhibitory action of mersalyl on microsomal drug oxidation: A rigid organization of the electron transport chain. Arch. Biochem. 143:318-329 (1971).
12. M. Bradford. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254 (1976).
13. F. Gonzalez. The molecular biology of the cytochrome P450s. Pharmacol. Rev. 40:243-287 (1989).
14. T. Nash. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem. J. 55:416-421 (1953).
15. M. Burke, S. Thompson, C. Elcombe, J. Halpert, T. Haaparanta and R. Mayer. Etoxy-, Pentoxy-, and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochrome P450s. Biochem. Pharmacol. 34:3337-3345 (1985).
16. L. Reinke and M. Moyer. P-nitrophenol hydroxylation a microsomal oxidation which is highly inducible by ethanol. Drug Metab. and Disp. 13:548-552 (1985).
17. J. Nishikawa, T. Yabe, A. Kast, and H. Albert. Circadian rhythm of the liver of male rats pre-treated with phenobarbital-II. Hexabarbital sleeping times and lipid contents in liver and serum. Chronoiol. Inter. 4:175-182 (1987).
18. 5-3b-hydroxysteriods and glucocorticoids in rat brain and plasma and human plasma. Prog. Clin. Biol. Res. 227A:451-465 (1987).
19. D. Simmons, McQuiddy, and C. Kasper. Induction of the hepatic mixed-function oxidase system by synthetic glucocorticoids. J. Biol. Chem. 262:326-332 (1987).
20. M. Paine, D. Shen, K. Kunze, J. Perkins, C. March, J. Mc Vicar, D. Barr, B. Gillies, and K. Thummel. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60(1): 14-24 (1996).
21. K. Thummel, D. O'Shea, M. Paine, D. Shen, K. Kunze, J. Perkins, and G. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59(5):491-502 (1996).
22. M. Paine, D. Shen, K. Kunze, J. Perkins, C. March, J. McVicar, D. Barr, B. Gillies, and K. Thummel. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60(1):14-24 (1996).
23. K. Thummel, D. O'Shea, M. Paine, D. Shen, K. Kunze, J. Perkins, and G. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59(5):491-502 (1996).